Breast Cancer Virtual Journal Club | Everolimus plus Weekly Paclitaxel and Trastuzumab in Patients with Metastatic Breast Cancer Pretreated with Trastuzumab |
Expert perspectives with Fabrice André, MD, PhD, interviewed by Sunil Verma, MD, MSEd, FRCPC.
This independent medical education activity features an expert interview with Fabrice André, MD, PhD, and Sunil Verma, MD, MSEd, FRCPC, focusing on the phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab (Andre F, et al. J Clin Oncol. 2010;28(34):5110-5115.).
Dr André briefly discusses the role of everolimus in reversing resistance to trastuzumab in patients with metastatic HER2-positive breast cancer. |
|
Audience | The information on this site is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before accessing the Webcast and slides. This site may contain information on products outside the approved indications where you practice. |
|
|
Support | This educational activity is supported by Novartis Oncology.
|
|
|
|
Featured Experts |
 |
|
Speaker
Fabrice André, MD, PhD
Institute Gustave Roussy
Villejuif, France
|
| |
|
|
 |
|
Interviewer
Sunil Verma, MD, MSEd, FRCPC
Toronto Sunnybrook Regional Cancer Center
Toronto, Canada
|
|
Activity Date | This Webcast is available from 13 January 2011 to 13 January 2012. |
|
